National Cooperative Drug Discovery Groups for Cancer

The summary for the National Cooperative Drug Discovery Groups for Cancer grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
National Cooperative Drug Discovery Groups for Cancer: The Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI) invites applications to continue the National Cooperative Drug Discovery Group (NCDDG) Program for the discovery of new and more effective anticancer treatments. This program will further the NIH Roadmap Initiatives ( and the NCI goal of eliminating the suffering and death due to cancer by the year 2015. For this Request for Applications (RFA), the term NCDDG will apply, whether the products are from natural sources or of synthetic or biological origin. Applications are sought from both new and re-competing NCDDGs (also called Groups). This RFA will support broad, innovative, interdisciplinary, multi- project approaches to the discovery of new, rationally based or natural-source derived anticancer treatments or strategies. The initiative provides a framework for interactions that will reduce the time from concept to product. A multi-institutional, public-private partnership approach involving academic, nonprofit, and/or commercial/industrial institutions with Government staff participation is envisioned because the creative talents in the required scientific disciplines are rarely available in a single institution. Although not required, the active participation of industry is encouraged because it will allow this segment of the scientific community to contribute its considerable intellectual and material resources. Further, the interaction of academic and non-profit research institutions with industry and Government will facilitate subsequent development and marketing of new therapies, although these latter activities are not within the scope of this RFA. Biological or molecular targets for drug discovery and the sources and types of natural products to be investigated will be selected by the applying Group. Subsequent studies required for development of new treatments (e.g., formulation development, large-scale production for clinical trials, or toxicology in support of Investigational New Drug Applications, etc.) as well as the clinical trial itself, are beyond the scope of this RFA. However, a timely evaluation of products is encouraged. The development of analogs of established or well-studied anticancer agents is not responsive to this RFA.
Federal Grant Title: National Cooperative Drug Discovery Groups for Cancer
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-05-001
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.395
CFDA Descriptions: Cancer Treatment Research
Current Application Deadline: No deadline provided
Original Application Deadline: May 19, 2004
Posted Date: Jan 20, 2004
Creation Date: Jun 18, 2004
Archive Date: Jun 18, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
Similar Government Grants
Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)
Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)
NCI Pediatric In Vivo Testing Program (U01 Clinical Trial Not Allowed)
NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed...
Limited Competition: Childhood Cancer Survivor Study (U24 Clinical Trial Required)
Breast and Prostate Cancer Data Quality and Patterns of Care Study
Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
Pediatric Phase 1/Pilot Consortium (U01)
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021